Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer

被引:4
作者
Takada, Koji [1 ]
Kashiwagi, Shinichiro [1 ]
Goto, Wataru [1 ]
Asano, Yuka [1 ]
Takahashi, Katsuyuki [2 ]
Morisaki, Tamami [1 ]
Takashima, Tsutomu [1 ]
Tomita, Shuhei [2 ]
Hirakawa, Kosei [1 ]
Ohira, Masaichi [1 ]
机构
[1] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan
[2] Osaka City Univ, Grad Sch Med, Dept Pharmacol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan
基金
日本学术振兴会;
关键词
Quality of life; Breast cancer; Prognostic marker; Preoperative chemotherapy; QOL-ACD-B; QUALITY-OF-LIFE; PATIENT-REPORTED OUTCOMES; PROGNOSTIC VALUE; SCORES; SURVIVAL; THERAPY; ADJUVANT; NEOADJUVANT; VALIDATION; CARES;
D O I
10.1007/s00432-018-2670-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Quality-of-life (QOL) has been reported to affect the prognosis of many types of cancer, and several studies used various QOL assessment tools to determine the relationship between QOL and cancer prognosis. In this study, QOL-Questionnaire for Cancer Patients Treated with Anti-Cancer Drugs-the Breast (QOL-ACD-B) was modified to be suitable for preoperative chemotherapy (POC) and was named the QOL-ACD-BP. A total of 300 patients were treated with POC after being diagnosed with breast cancer between February 2007 and December 2016 at our institute. We evaluated novel evaluation scale for QOL (QOL-ACD-BP) before and after POC in a retrospective manner. In the multivariate analysis with overall survival, the high QOL before [p = 0.048, hazard ratio (HR) 0.441] or after POC (p = 0.030, HR 0.273) was an independent factor. Our study shows that QOL after POC may also affect prognosis and supported the importance of maintaining QOL in cancer treatment. In patients with breast cancer treated with POC, QOL-ACD-BP, which is a new QOL evaluation index, was found to be a useful tool for predicting the patients' prognosis.
引用
收藏
页码:1547 / 1559
页数:13
相关论文
共 36 条
[31]   Validation of the flemish CARES, a quality of life and needs assessment tool for cancer care [J].
Schouten, Bojoura ;
Hellings, Johan ;
Van Hoof, Elke ;
Vankrunkelsven, Patrick ;
Bulens, Paul ;
Buntinx, Frank ;
Mebis, Jeroen ;
Vandijck, Dominique ;
Schrooten, Ward .
BMC CANCER, 2016, 16
[32]   The prognostic value of quality-of-life scores: Preliminary results of an analysis of patients with breast cancer [J].
Shimozuma, K ;
Sonoo, H ;
Ichihara, K ;
Tanaka, K .
SURGERY TODAY, 2000, 30 (03) :255-261
[33]   Comparison of EQ-5D Scores among Anthracycline-Containing Regimens followed by Taxane and Taxane-Only Regimens for Node-Positive Breast Cancer Patients after Surgery: The N-SAS BC 02 Trial [J].
Shiroiwa, Takeru ;
Fukuda, Takashi ;
Shimozuma, Kojiro ;
Kuranami, Masaru ;
Suemasu, Kimito ;
Ohashi, Yasuo ;
Watanabe, Toru .
VALUE IN HEALTH, 2011, 14 (05) :746-751
[34]  
SPIEGEL D, 1989, LANCET, V2, P888
[35]   Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial [J].
Watanabe, Toru ;
Sano, Muneaki ;
Takashima, Shigemitsu ;
Kitaya, Tomoki ;
Tokuda, Yutaka ;
Yoshimoto, Masataka ;
Kohno, Norio ;
Nakagami, Kazuhiko ;
Iwata, Hiroji ;
Shimozuma, Kojiro ;
Sonoo, Hiroshi ;
Tsuda, Hitoshi ;
Sakamoto, Goi ;
Ohashi, Yasuo .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1368-1374
[36]  
Wolmark N, 2001, J Natl Cancer Inst Monogr, P96